Biopharmaceutical benchmarks 2018
Copyright policy )Biopharmaceutical benchmarks 2018
Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.
- University of Limerick Ireland
Biological Products, Drug Industry, United States Food and Drug Administration, Antibodies, Monoclonal, Recombinant Proteins, United States, Benchmarking, Nucleic Acids, Animals, Humans, European Union, Biosimilar Pharmaceuticals, Drug Approval, Biotechnology
Biological Products, Drug Industry, United States Food and Drug Administration, Antibodies, Monoclonal, Recombinant Proteins, United States, Benchmarking, Nucleic Acids, Animals, Humans, European Union, Biosimilar Pharmaceuticals, Drug Approval, Biotechnology
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).838 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 0.1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.01%
Citations provided by BIP!Popularity provided by BIP!